The Patent Landscape of Nanomedicines

Main Article Content

Diana Bowman Antonio D Marino Douglas J Sylvester



Article Details

How to Cite
BOWMAN, Diana; MARINO, Antonio D; SYLVESTER, Douglas J. The Patent Landscape of Nanomedicines. Medical Research Archives, [S.l.], v. 5, n. Issue 9, sep. 2017. ISSN 2375-1924. Available at: <>. Date accessed: 29 nov. 2023.
Research Articles


[1] Grand View Research 2017. Nanomedicine Market Size Worth $350.8 Billion By 2025 | CAGR: 11.2%. Available at:
[2] Bowman, DM & Gatof, J. (2015). Reviewing the regulatory barriers for nanomedicine: global questions and challenges. Nanomedicine, 10(21), 3275-3286.
[3] See Elan Pharma Int'l v. Abraxis Bioscience, No. 06-438 GMS, 2008 U.S. Dist. LEXIS 125886 (D. Del. June 16, 2008).
[4] Bolado, C. 2011. Celgene Strikes $78M Deal In Elan Abraxane IP Suit, Law360, 24 February. Available at:
[5] Bowman, DM, Sylvester, DJ and Marino, A. 2017. ‘Returning to the Patent Landscapes for Nanotechnology; Assessing the garden that it has grown into,’ in Sarah J Hurst and Emily Day (eds), Biomedical Nanotechnology: Methods and Protocols, New York: Springer, pp.315-448.
[6] Tinkle, S, McNeil, SE, Mühlebach, S, Bawa, R, Borchard, G, Barenholz, YC, ... & Desai, N. 2014. Nanomedicines: addressing the scientific and regulatory gap. Annals of the New York Academy of Sciences, 1313(1), 35-56.
[7] DeVol, RC, et al. 2011. The Global Biomedical Industry: Preserving U.S. Leadership, Milken Institute, September. Available at:
[8] U.S. Constitution, article I, § 8, clause
[9] Heller, MA and Eisenberg, RS 1998. Can patents deter innovation? The anticommons in biomedical research. Science, 280(5364), 698-701.
[10] ETC Group 2005. Nanotech’s “Second Nature” Patents: Implications for the Global South, June. Available at:
[11] Initiative for Medicines Access and Knowledge 2013. Patent Landscape Report for Pegylated Interferon Alfa 2A and 2B, February. Available at:
[12] Enzon Pharmaceuticals 2001. Enzon Announces Schering-Plough In-Licensing Agreement with Roche Resolving Peginterferon Patent Disputes, 13 August. Available at:
[13] Romero‐Gómez, M, Planas, R, Ampuero, J, Sola, R, García‐Samaniego, J, Diago, M, ... and Turnes, J. 2013. Meta‐analysis: pegylated interferon α‐2a achieves higher early virological responses than α‐2b in chronic hepatitis C. Alimentary pharmacology & therapeutics, 37(11), 1065-1073.
[14] Mossof, A. 2011. The Rise and Fall of the First American Patent Thicket: The Sewing Machine War of the 1850s’. Arizona Law Review, 53, 165.
[15] Cutler, M. 2015. 3 Years Of IPR: A Look at The Stats, Law360, 9 October. Available at:
[16] Brachmann, S. 2017. PTAB ends Kyle Bass IPRs targeting Acorda patents on Ampyra MS treatment with no findings of obviousness, IP Watchdog, 14 March. Available at:
[17] Quinn, G. 2017. Patent Reform 2017: Changes coming from the Judiciary, Legislative and Executive Branches, IP Watchdog. Available at: